Table 2.

The reasons for the switch to TAF/FTC/BIC among HAART-experienced patients.

Reasons	Values (n = 1684)
Simplify regimens	990 (58.79)
Osteoporosis or osteopenia	375 (22.27)
Liver dysfunction	231 (13.72)
Decline to taking ART with food	215 (12.77)
Virological failure	116 (6.89)
Renal dysfunction	90 (5.34)
CNS side effects	47 (2.79)
Dyslipidemia	30 (1.78)

Data were presented as n (%). These reasons were not mutually exclusive. ART: Antiretroviral therapy; CNS: Central nervous system; HAART: Highly active antiretroviral therapy; TAF/FTC/BIC: Tenofovir alafenamide/emtricitabine/bictegravir sodium.